26 July 2024
MedAdvisor (MDR): Q4 Update On Track
MedAdvisor had another strong quarter of topline growth in the US and ANZ, while gross margins also improved.
20 December 2023
Neuren Pharmaceuticals (NEU): It Keeps Getting Better
NEU released impressive efficacy and safety results from the first of four single-arm Phase 2 trials evaluating NNZ-2591 (n=18).